Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2003

View Archived Issues

Bayer presents novel VR1 antagonists for urinary incontinence, pain, etc.

New thrombolytic carboxypeptidase U inhibitors in early development at Merck

Sanofi-Synthelabo claims new inhibitors of Abeta production for AD and other disorders

New series of anticytomegalovirus agents covered by Bayer patent

Alphav integrin antagonists discovered by Merck KGaA researchers

GSK scientists identify new 5-HT6 receptor ligands for depression, anxiety and other uses

Potent and selective COX-2 inhibitors prepared and tested at GSK

Cathepsin K inhibitors and their use in osteoporosis reported by GSK

Virginia Commonwealth U. researchers design nonopioid and non-nicotinic analgesics

New antibacterial and antifungal MUC7-derived peptides

GTI-2040 awarded orphan drug status for renal cell cancer

Basulin shows comparable pharmacokinetic profile to Lantus in healthy volunteers

Allergan and ExonHit collaborate on drug discovery, development & commercialization

Elan and Ingenium to develop pain management therapeutics

Brigham Young University and Merck & Co. sign COX licensing agreement

New data on efalizumab in plaque psoriasis

Antithrombotic and antiinflammatory effects described for drotrecogin alfa (activated) in sepsis

Improvement of pain associated with major depression after duloxetine administration

Intrathecal ziconotide in pain

Good safety profile established for IDEC-152 in patients with seasonal allergic rhinitis

NIH licensing a class of gp100 cancer antigens

Novel cyclic polyamines that release NO in a biphasic manner available for licensing

Licenses offered for peptide inhibitors of Yersinia YopH as potential treatments for plague

FTC staff completes review of Pfizer-Pharmacia merger

Amendment to miglustat NDA submitted

Independent panel examines AZD-3582 trial protocol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...